Guided Therapeutics (GTHP) Notes Payables (2011 - 2026)

Guided Therapeutics has disclosed Notes Payables across 16 years of filings, most recently posting $296000.0 for Q2 2026.

• In Q2 2026, Notes Payables fell 29.69% year-over-year to $296000.0; the TTM figure through Jun 2026 stood at $296000.0 (down 29.69% YoY), while the FY2025 annual figure was $347000.0, up 149.64% from the prior year.
• Notes Payables came in at $296000.0 for Q2 2026 at Guided Therapeutics, up from $264000.0 in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $745000.0 in Q1 2022 to a low of $23000.0 in Q1 2023.
• Average Notes Payables over 5 years is $256176.5, with a median of $228000.0 recorded in 2024.
• Year-over-year, Notes Payables jumped 597.59% in 2022 and sank 96.91% in 2023.
• Over 5 years, Notes Payables stood at $57000.0 in 2022, then climbed by 3.51% to $59000.0 in 2023, then surged by 135.59% to $139000.0 in 2024, then surged by 149.64% to $347000.0 in 2025, then retreated by 14.7% to $296000.0 in 2026.
• Per Business Quant data, the three most recent Notes Payables figures were $296000.0 in Q2 2026, $264000.0 in Q1 2026, and $347000.0 in Q4 2025.